CHF23.30
1.69% yesterday
SIX Swiss Exchange, Sep 19, 05:31 pm CET
ISIN
CH0325814116
Symbol
KURN

Kuros Biosciences Stock price

CHF23.30
-4.50 16.19% 1M
+3.74 19.12% 6M
+1.95 9.13% YTD
+2.45 11.75% 1Y
+21.55 1,231.43% 3Y
+20.93 883.12% 5Y
-22.46 49.08% 10Y
-3,581.44 99.35% 20Y
SIX Swiss Exchange, Closing price Fri, Sep 19 2025
-0.40 1.69%
ISIN
CH0325814116
Symbol
KURN
Industry

Key metrics

Basic
Market capitalization
CHF867.1m
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | 451.0
P/S
9.3 | 8.0
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
69.5%
Return on Equity
-7.3%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
CHF93.7m | CHF109.0m
EBITDA
CHF1.1m | CHF15.8m
EBIT
CHF-1.6m | CHF2.8m
Net Income
CHF-5.6m | -
Free Cash Flow
CHF-140.0k
Growth (TTM | estimate)
Revenue
92.7% | 46.3%
EBITDA
144.5% | 1,979.0%
EBIT
69.0% | 2,472.2%
Net Income
34.9% | -
Free Cash Flow
96.8%
Margin (TTM | estimate)
Gross
83.3%
EBITDA
1.2% | -
EBIT
-1.7%
Net
-6.0% | -
Free Cash Flow
-0.2%
More
EPS
CHF-0.1
FCF per Share
-
Short interest
-
Employees
122
Rev per Employee
CHF610.0k
Show more

Is Kuros Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,012 stocks worldwide.

Kuros Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Kuros Biosciences forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Kuros Biosciences forecast:

Buy
88%
Hold
13%

Financial data from Kuros Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
94 94
93% 93%
100%
- Direct Costs 16 16
50% 50%
17%
78 78
104% 104%
83%
- Selling and Administrative Expenses 73 73
78% 78%
78%
- Research and Development Expense 6.81 6.81
24% 24%
7%
1.10 1.10
145% 145%
1%
- Depreciation and Amortization 2.70 2.70
0% 0%
3%
EBIT (Operating Income) EBIT -1.60 -1.60
69% 69%
-2%
Net Profit -5.64 -5.64
35% 35%
-6%

In millions CHF.

Don't miss a Thing! We will send you all news about Kuros Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals, and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment offers Fibrin-PTH, a drug-biologic combination which promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The Legacy portfolio segment is involved in all other products that do not belong to the group's core business strategy. The company was founded by Didier Cowling in 2000 and is headquartered in Schlieren, Switzerland.

Head office Switzerland
CEO Christopher Fair
Employees 122
Founded 2000
Website kurosbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today